[1]
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374(9686): 324-39.
[2]
Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17(1): 27-38.
[3]
Herrmann J, Yang EH, Iliescu CA, et al. Vascular toxicities of cancer therapies: The old and the new - an evolving avenue. Circulation 2016; 133(13): 1272-89.
[4]
Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372(2): 142-52.
[5]
Chari A, Mezzi K, Zhu S, Werther W, Felici D, Lyon AR. Incidence and risk of hypertension in patients newly treated for multiple myeloma: A retrospective cohort study. BMC Cancer 2016; 16(1): 912.
[6]
Kistler KD, Kalman J, Sahni G, et al. Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: An observational, retrospective, cohort study. Clin Lymphoma Myeloma Leuk 2017; 17(2): 89-96.e3.
[7]
Groll M, Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: A structural approach. Biochim Biophys Acta 2004; 1695(1-3): 33-44.
[8]
Crawford LJ, Irvine AE. Targeting the ubiquitin proteasome system in haematological malignancies. Blood Rev 2013; 27(6): 297-304.
[9]
Stangl K, Stangl V. The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc Res 2010; 85(2): 281-90.
[10]
Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 2013; 41(1): 230-7.
[11]
Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67(13): 6383-91.
[12]
Govers R, de Bree P, Rabelink TJ. Involvement of the proteasome in activation of endothelial nitric oxide synthase. Life Sci 2003; 73(17): 2225-36.
[13]
Chen-Scarabelli C, Corsetti G, Pasini E, et al. Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity. EBioMedicine 2017; 21: 206-12.
[14]
Chen Y, Ooi M, Lim SF, et al. Thrombotic microangiopathy during carfilzomib use: Case series in Singapore. Blood Cancer J 2016; 6(7): e450.
[15]
Bringhen S, De Wit E, Dimopoulos MA. New agents in multiple myeloma: An examination of safety profiles. Clin Lymphoma Myeloma Leuk 2017; 17(7): 391-407.e5.
[16]
Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: An endothelial effect? Blood Cancer J 2016; 6: e384.
[17]
Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv 2017; 1(7): 449-54.
[18]
Ranek MJ, Zheng H, Huang W, et al. Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload. J Mol Cell Cardiol 2015; 85: 273-81.
[19]
Herrmann J, Saguner AM, Versari D, et al. Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 2007; 101(9): 865-74.
[20]
Spur EM, Althof N, Respondek D, et al. Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes. Toxicology 2016; 353-354: 34-47.
[21]
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(36): 2768-801.
[22]
Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 31(10): 1925-38.
[23]
Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24(11): 987-1003.
[24]
Lopez-Fernandez T. Martín García A2, Santaballa Beltrán A, et al. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed), 2017; 70(6): 474-86 In:
[25]
Mozos I, Borzak G, Caraba A, Mihaescu R. Arterial stiffness in hematologic malignancies. OncoTargets Ther 2017; 10: 1381-8.
[26]
Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: A report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)dagger. Eur Heart J Cardiovasc Imaging 2015; 16(6): 577-605.
[27]
Perrone-Filardi P, Coca A, Galderisi M, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging 2017; 18(9): 945-60.
[28]
Reboldi G, Angeli F, de Simone G, Staessen JA, Verdecchia P. Cardio-Sis Investigators. Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension 2014; 63(3): 475-82.
[29]
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for
cardiac chamber quantification by echocardiography in adults: An
update from the american society of echocardiography and the European
association of cardiovascular imaging. J Am Soc Echocardiogr
2015; 28(1): 1-39 e14.
[30]
Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013; 61(1): 77-84.
[31]
Gong FF, Campbell DJ, Prior DL. Noninvasive cardiac imaging and the prediction of heart failure progression in preclinical stage A/B subjects. JACC 2017; 10(12): 1504-19.
[32]
Yang H, Marwick TH, Fukuda N, et al. Improvement in strain
concordance between two major vendors after the strain standardization
initiative. J Am Soc Echocardiogr 2015; 28(6): 642-8 e7.
46
2